Founding Member
John Crumpler
General Partner, Hatteras Venture Partners
John co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. After a decade in politics and public policy, he was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing. Following E-Comm’s acquisition by XcelleNet, Inc. (XNET), John ran the services division there until the company was acquired by Sterling Commerce (SE). Following the acquisition John founded Hatteras with Clay Thorp.
At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations.
With his partners at Hatteras John has helped build a seed and early stage venture capital partnership with over $600 million under management in six funds. In that time, he has served on the boards of Synthematix, a chemistry informatics company that was acquired by Symyx Technologies (SMMX); Clinverse, a financial lifecycle management technology provider to contract research organizations (CROs) and pharmaceutical companies, acquired by Bioclinica, Inc.; Bivarus, a survey-based health analytics company acquired by Press Ganey; NurseGrid, the nation’s most widely distributed nurse scheduling platform, acquired by HealthStream; and Medfusion, a leading patient engagement platform, acquired by NextGen. John currently serves on the boards of Iris Healthcare, Elligo Health Research, Wildflower Health, Jumo Health, and as an observer at SafeRide and Clinipace Worldwide. He holds an A.B. from Harvard University.
CEO Cancer Gold Standard™
Gold Standard Employer
Since 2016
The CEO Cancer Gold Standard is the best way I know for any organization to make a real difference in the fight against cancer.
John Crumpler
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. The firm will typically invest in companies located in the research-driven regions of North Carolina and the Southeastern United States, which are undercapitalized in comparison to New England and California.
Core to the mission of Hatteras Venture Partners is a belief that entrepreneurial innovation will create valuable new products that will transform the practice of medicine and create value for our investors. As entrepreneurs, operators, and investors, we are dedicated to the success of our companies and to the men and women who create them.
Founded in 2000 and based in Durham, NC, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With five funds, the firm has approximately $350 million under management.
Hatteras is an Innovation to Impact sponsor of the Council for Entrepreneurial Development, a member of NCBIO, and an active volunteer in support of North Carolina and Southeast regional biotech activities.
